Molecular-biology markers in the serum of patients with primary bone tu- TOC \o "1-5" \h \z mors
Abstract
We studied type 1 and 2 fibroblast growth factors (FGF-1, FGF-2) and endostatin in the serum obtained from 58 untreated bone tumor patients and in the serum of 21 practically healthy subjects. FGF-1, FGF-2 and endostatin were measured by enzyme immunoassay in the serum using «R&D» kits (USA). Frequency of FGF-1 determination in serum was in 2,5 times higher in patients with bone tumors than in healthy subjects (p=0,004). All samples contained FGF-2 and endostatin. Endostatin levels in practically healthy subjects were lower than in patients with bone tumors (p=0,005). FGF-1 levels in patients with osteosarcoma were significantly lower than in patients with chondrosarcoma (p<0,05), there were no significant differences in FGF-2 concentrations in patients with various types of affected bone. No significant correlations were found between FGF-1, FGF-2 and endostatin levels in practically healthy subjects and in patients with bone tumors. We demonstrated differences in 3-years overall survival in patients with bone sarcomas depending on serum FGF-1 and endostatin levels.
About the Authors
N. E. Kushlinsky
N.N. Blokhin Russian Cancer Research Center
Russian Federation
Russian Federation
I. V. Babkina
N.N. Blokhin Russian Cancer Research Center
Russian Federation
Russian Federation
Yu. N. Soloviev
N.N. Blokhin Russian Cancer Research Center
Russian Federation
Russian Federation
I. V. Bulicheva
N.N. Blokhin Russian Cancer Research Center
Russian Federation
Russian Federation
G. N. Machak
N.N. Blokhin Russian Cancer Research Center
Russian Federation
Russian Federation
References
1. Bodo M., Lilli C., Bellucci C. et al. Basic fibroblast growth factor autocrine loop controls human osteosarcoma phenotyping and differentiation. Molecular Medicine. 2002, v. 8, No.7, p.393-404.
2. Powers C.J., McLeskey S.W., Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocrine-Related Cancer. 2000, v. 11, p.165-197.
3. Valta M.P., Hentunen T., Qu Q. et al. Regulation of osteoblast differentiation: a novel function for fibroblast growth factor 8. Endocrinology. 2006, v. 147, No.5, p. 2171-2182.
4. Solan J.L., Deftos L.J., Goding J.W., Terkeltaub R.A. Expression of the nucleoside triphosphate pyrophospho- hydrolase PC-1 is induced by basic fibroblast growth factor (bFGF) and modulated by activation of the protein kinase A and C pathways in osteoblast-like osteosarcoma cells. J. Bone Miner. Res. 1996, v. 11, No. 2, p.183-192.
5. Kwabi-Addo B., Ozen M., Ittmann M. The role of fibroblast growth factors and their receptors in prostate cancer. Endocrine-Related Cancer. 2000, v. 11, p. 709-724.
6. Roomi M.W., Roomi N., Ivanov V. Inhibitory effect of a mixture containing ascorbic acid, lysine, proline and green tea extract on critical parameters in angiogenesis. Oncol. Rep. 2005, v. 14, No. 4, p. 807-815.
7. Jang J.H. Identification and characterization of soluble isoform of fibroblast growth factor receptor 3 in human SaOS- 2 osteosarcoma cells. Biochem. Biophys. Res. Commun. 2002, v. 292, No. 2, p. 378-382.
8. Jung H.S., Kim H.S., Lee M.J. et al. Arsenic trioxid concentration determines the fate of Ewing’s sarcoma family tumors and neuroblastoma cells in vitro. FEBS Lett. 2006, v. 580, No. 20, p. 4969-4975.
9. Ma C., Bower K.A., Chen G. et al. Interaction between ERK and GSK3beta mediates basic fibroblast growth factor- induced apoptosis in SK-N-MC neuroblastoma cells. J. Biol. Chem. 2008, v. 283, No.14, p. 9248-9256.
10. Киселев С.М., Луценко С.В., Северин С.Е., Северин Е.С. Ингибиторы опухолевого ангиогенеза. Биохимия. 2003, том 68, № 5, c. 611-631.
11. Луценко С.В., Киселев С.М., Фельдман Н.Б., Северин С.Е. Молекулярные механизмы ангиогенеза в физиологических и патологических процесса. Под ред. М.А. Пальцева. «Введение в молекулярную медицину». М., «Медицина». 2004, с. 446-495.
12. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nature Med. 2000, v. 6, No. 4, p. 389-395.
13. O’Reilly M.S., Boehm T, Shing Y, Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997, v. 88, p. 277-285.
14. Kaya M., Wada T., Nagoya S., Yamashita T Prevention of postoperative progression of pulmonary metastases in osteosarcoma by antiangiogenic therapy using endostatin. J. Orthop. Sci. 2007, v. 12, No. 6, p. 562-567.
15. Dutour A., Monteil J., Paraf E. et al. Endostatin cDNA/ cationic liposome complexes as a promising therapy to prevent lung metastases in osteosarcoma: study in a human-like rat orthotopic tumor. Mol. Ther. 2005, v. 11, No. 2, p. 311-319.
16. Kaya M., Wada T, Nagoya S. et al. Concomitant tumour resistance in patients with osteosarcoma. A clue to a new therapeutic strategy. J. Bone Joint Surg. Br. 2004, v. 86, No. 1, p. 143-147.
Review
For citations:
Kushlinsky N.E., Babkina I.V., Soloviev Yu.N., Bulicheva I.V., Machak G.N. Molecular-biology markers in the serum of patients with primary bone tu- TOC \o "1-5" \h \z mors. Bone and soft tissue sarcomas, tumors of the skin. 2009;(1):79-82. (In Russ.)
Views:
60
Email this article 
